CL2017002680A1 - Construcciones de calicheamicina y sus métodos de uso - Google Patents

Construcciones de calicheamicina y sus métodos de uso

Info

Publication number
CL2017002680A1
CL2017002680A1 CL2017002680A CL2017002680A CL2017002680A1 CL 2017002680 A1 CL2017002680 A1 CL 2017002680A1 CL 2017002680 A CL2017002680 A CL 2017002680A CL 2017002680 A CL2017002680 A CL 2017002680A CL 2017002680 A1 CL2017002680 A1 CL 2017002680A1
Authority
CL
Chile
Prior art keywords
calicheamycin
methods
constructions
conjugates
adc
Prior art date
Application number
CL2017002680A
Other languages
English (en)
Inventor
Julia Gavrilyuk
Vikram Natwarsinhji Sisodiya
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of CL2017002680A1 publication Critical patent/CL2017002680A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>Se proveen conjugados de fármaco y anticuerpo (ADC) que comprenden calicheamicina y métodos de uso de los mismos para el tratamiento de trastornos proliferativos.</p>
CL2017002680A 2015-04-21 2017-10-20 Construcciones de calicheamicina y sus métodos de uso CL2017002680A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562150693P 2015-04-21 2015-04-21

Publications (1)

Publication Number Publication Date
CL2017002680A1 true CL2017002680A1 (es) 2018-04-27

Family

ID=57144229

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002680A CL2017002680A1 (es) 2015-04-21 2017-10-20 Construcciones de calicheamicina y sus métodos de uso

Country Status (20)

Country Link
US (1) US20180133337A1 (es)
EP (1) EP3285807A4 (es)
JP (1) JP2018515457A (es)
KR (1) KR20170139110A (es)
CN (1) CN107849146A (es)
AR (1) AR104333A1 (es)
AU (1) AU2016250537A1 (es)
BR (1) BR112017022682A2 (es)
CA (1) CA2983158A1 (es)
CL (1) CL2017002680A1 (es)
CO (1) CO2017010692A2 (es)
EA (1) EA201792312A1 (es)
HK (1) HK1246194A1 (es)
IL (1) IL255161A0 (es)
MA (1) MA41959A (es)
PE (1) PE20180599A1 (es)
PH (1) PH12017501930A1 (es)
SG (1) SG11201708629VA (es)
TW (1) TW201713363A (es)
WO (1) WO2016172273A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019013421A (es) 2017-05-10 2020-02-05 Sanofi Sa Enlazadores peptidicos y conjugados de criptoficina, utiles en la terapia, y su preparacion.
EP3720504A1 (en) 2017-12-06 2020-10-14 Synaffix B.V. Enediyne conjugates
MA51453A (fr) * 2018-05-30 2020-09-23 Abbvie Stemcentrx Llc Conjugués anticorps anti-sez6-médicaments et procédés d'utilisation
CA3129585A1 (en) * 2019-02-18 2020-08-27 Medivir Aktiebolag Methods for treating liver cancers using an orally administered dioxolane nucleotide in combination with an anti-pd1 or anti-pdl1 monoclonal antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6576746B2 (en) * 1998-10-13 2003-06-10 Immunomedics, Inc. Site-specific labeling of disulfide-containing targeting vectors
LT1507556T (lt) * 2002-05-02 2016-10-10 Wyeth Holdings Llc Kalicheamicino darinio ir nešiklio konjugatai
US8815226B2 (en) * 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2927227A4 (en) * 2013-01-03 2015-12-30 Celltrion Inc ANTIBODY CONCENTRATOR REMEDY CONJUGATE, METHOD OF MANUFACTURING THEREOF, AND ANTIBODY TOGETHER THEREWITH
EP3892294A1 (en) * 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions

Also Published As

Publication number Publication date
CA2983158A1 (en) 2016-10-27
CO2017010692A2 (es) 2018-01-31
MA41959A (fr) 2018-02-28
PH12017501930A1 (en) 2018-03-19
AU2016250537A1 (en) 2018-11-08
JP2018515457A (ja) 2018-06-14
WO2016172273A1 (en) 2016-10-27
TW201713363A (zh) 2017-04-16
SG11201708629VA (en) 2017-11-29
CN107849146A (zh) 2018-03-27
EP3285807A1 (en) 2018-02-28
EP3285807A4 (en) 2018-12-26
PE20180599A1 (es) 2018-04-09
IL255161A0 (en) 2017-12-31
BR112017022682A2 (pt) 2018-07-10
AR104333A1 (es) 2017-07-12
US20180133337A1 (en) 2018-05-17
EA201792312A1 (ru) 2018-06-29
HK1246194A1 (zh) 2018-09-07
KR20170139110A (ko) 2017-12-18

Similar Documents

Publication Publication Date Title
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
CL2017002422A1 (es) Derivados de maitansinoide, conjugados de los mismos, y métodos de uso.
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
ECSP18049762A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
CL2017002150A1 (es) Receptores de antígeno quiméricos anti-dll3 y métodos de uso
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CR20170240A (es) Anticuerpos anti-interleucina-33 y sus usos
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
PE20160870A1 (es) Anticuerpos anti-claudina novedosos y metodos de uso
CR20190271A (es) Anticuerpos antitau y métodos de uso
PE20150646A1 (es) Metodos de tratamiento de una tauopatia
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
CL2016001743A1 (es) Conjugados de anticuerpo-fármaco (adc) de duocarmicina para su uso en el tratamiento de cáncer de endometrio.
CL2017001661A1 (es) Compuestos biciclicos fusionados para el tratamiento de una enfermedad.
CR20150549A (es) Compuestos heterocíclicos y sus usos
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
CL2018001139A1 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos.